Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07438405 · ClinicalTrials.gov registry record · Phase 2
An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
A Phase 2 study, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07438405 is a Phase 2 study that is actively recruiting participants, run by Amgen. The registered enrollment target is 30 participants.
The verdict
NCT07438405, a Phase 2 study, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The main objective of this trial is to assess the efficacy of AMG 732 in participants with thyroid eye disease (TED) who are defined as primary nonresponders or relapsed during the safety follow-up in the parent trial (NCT06401044).
Interventions
- DRUG AMG 732
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-05-07 |
| Est. Completion | 2028-07-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07438405
The ClinicalTrials.gov registry entry for NCT07438405 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 732 is the first listed.
NCT07438405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07438405 about?
NCT07438405 is a clinical study titled "An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease". The main objective of this trial is to assess the efficacy of AMG 732 in participants with thyroid eye disease (TED) who are defined as primary nonresponders or relapsed during the safety follow-up in the parent trial (NCT06401044).
What is the current status of trial NCT07438405?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-05-07. Estimated completion is 2028-07-14.
What interventions are being tested in trial NCT07438405?
The interventions under investigation include: AMG 732 (DRUG).
Who is sponsoring clinical trial NCT07438405?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.